Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Similar Items

• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib
  od: Sami Morin-Ben Abdallah, i dr.
  Izdano: (2017-05-01)
• Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation–positive advanced non-small-cell lung cancer
  od: Abdallah, S. Morin–Ben, i dr.
  Izdano: (2018)
• Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib
  od: Hirsh, Vera
  Izdano: (2015)
• Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?
  od: Abdallah, S. Morin–Ben, i dr.
  Izdano: (2018)
• Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
  od: Hirsh, V.
  Izdano: (2011)